vs
FREQUENCY ELECTRONICS INC（FEIM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是FREQUENCY ELECTRONICS INC的1.8倍（$30.3M vs $17.1M），FREQUENCY ELECTRONICS INC净利率更高（10.5% vs -221.3%，领先231.9%），REGENXBIO Inc.同比增速更快（43.0% vs 8.3%），FREQUENCY ELECTRONICS INC自由现金流更多（$-1.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.8%）
超电子控股是一家英国国防与安全企业，曾在伦敦证券交易所上市，是富时250指数成分股之一，后被隶属于安宏资本的科巴姆公司收购。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FEIM vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$17.1M
营收增速更快
RGNX
高出34.7%
8.3%
净利率更高
FEIM
高出231.9%
-221.3%
自由现金流更多
FEIM
多$51.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
11.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.1M | $30.3M |
| 净利润 | $1.8M | $-67.1M |
| 毛利率 | 38.2% | — |
| 营业利润率 | 10.0% | -190.0% |
| 净利率 | 10.5% | -221.3% |
| 营收同比 | 8.3% | 43.0% |
| 净利润同比 | -32.1% | -31.2% |
| 每股收益（稀释后） | $0.18 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FEIMRGNX
| Q4 25 | $17.1M | $30.3M | ||
| Q3 25 | $13.8M | $29.7M | ||
| Q2 25 | $20.0M | $21.4M | ||
| Q1 25 | $18.9M | $89.0M | ||
| Q4 24 | $15.8M | $21.2M | ||
| Q3 24 | $15.1M | $24.2M | ||
| Q2 24 | $15.6M | $22.3M | ||
| Q1 24 | $13.7M | $15.6M |
净利润FEIMRGNX
| Q4 25 | $1.8M | $-67.1M | ||
| Q3 25 | $634.0K | $-61.9M | ||
| Q2 25 | $3.2M | $-70.9M | ||
| Q1 25 | $15.4M | $6.1M | ||
| Q4 24 | $2.7M | $-51.2M | ||
| Q3 24 | $2.4M | $-59.6M | ||
| Q2 24 | $2.6M | $-53.0M | ||
| Q1 24 | $130.0K | $-63.3M |
毛利率FEIMRGNX
| Q4 25 | 38.2% | — | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 48.2% | 70.2% | ||
| Q3 24 | 44.4% | 48.8% | ||
| Q2 24 | 40.3% | 52.5% | ||
| Q1 24 | 22.6% | 72.6% |
营业利润率FEIMRGNX
| Q4 25 | 10.0% | -190.0% | ||
| Q3 25 | 2.6% | -176.3% | ||
| Q2 25 | 16.4% | -296.3% | ||
| Q1 25 | 18.3% | 13.6% | ||
| Q4 24 | 16.5% | -242.1% | ||
| Q3 24 | 15.7% | -256.6% | ||
| Q2 24 | 16.0% | -251.3% | ||
| Q1 24 | -3.4% | -408.8% |
净利率FEIMRGNX
| Q4 25 | 10.5% | -221.3% | ||
| Q3 25 | 4.6% | -208.3% | ||
| Q2 25 | 16.0% | -331.8% | ||
| Q1 25 | 81.4% | 6.8% | ||
| Q4 24 | 16.8% | -241.3% | ||
| Q3 24 | 16.1% | -246.3% | ||
| Q2 24 | 16.9% | -237.7% | ||
| Q1 24 | 0.9% | -405.4% |
每股收益（稀释后）FEIMRGNX
| Q4 25 | $0.18 | $-1.30 | ||
| Q3 25 | $0.07 | $-1.20 | ||
| Q2 25 | $0.33 | $-1.38 | ||
| Q1 25 | $1.60 | $0.12 | ||
| Q4 24 | $0.28 | $-0.99 | ||
| Q3 24 | $0.25 | $-1.17 | ||
| Q2 24 | $0.28 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.5M | $102.7M |
| 总资产 | $92.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FEIMRGNX
| Q4 25 | $3.0M | $230.1M | ||
| Q3 25 | $4.5M | $274.2M | ||
| Q2 25 | $4.7M | $323.3M | ||
| Q1 25 | $5.5M | $267.9M | ||
| Q4 24 | $9.7M | $234.7M | ||
| Q3 24 | $16.2M | $255.5M | ||
| Q2 24 | $18.3M | $290.4M | ||
| Q1 24 | $11.7M | $338.7M |
股东权益FEIMRGNX
| Q4 25 | $58.5M | $102.7M | ||
| Q3 25 | $56.3M | $161.5M | ||
| Q2 25 | $55.6M | $213.7M | ||
| Q1 25 | $51.8M | $274.2M | ||
| Q4 24 | $36.2M | $259.7M | ||
| Q3 24 | $33.2M | $301.4M | ||
| Q2 24 | $39.8M | $348.3M | ||
| Q1 24 | $36.7M | $390.7M |
总资产FEIMRGNX
| Q4 25 | $92.3M | $453.0M | ||
| Q3 25 | $93.2M | $525.2M | ||
| Q2 25 | $93.7M | $581.0M | ||
| Q1 25 | $86.4M | $490.9M | ||
| Q4 24 | $77.8M | $466.0M | ||
| Q3 24 | $84.3M | $519.1M | ||
| Q2 24 | $83.3M | $569.4M | ||
| Q1 24 | $77.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-523.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -6.6% | -174.0% |
| 资本支出强度资本支出/营收 | 3.6% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.29× | — |
| 过去12个月自由现金流最近4个季度 | $-5.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FEIMRGNX
| Q4 25 | $-523.0K | $-52.3M | ||
| Q3 25 | $1.2M | $-56.0M | ||
| Q2 25 | $-155.0K | $-49.3M | ||
| Q1 25 | $-3.6M | $33.6M | ||
| Q4 24 | $3.8M | $-31.6M | ||
| Q3 24 | $-1.5M | $-40.5M | ||
| Q2 24 | $7.5M | $-45.5M | ||
| Q1 24 | $4.2M | $-55.5M |
自由现金流FEIMRGNX
| Q4 25 | $-1.1M | $-52.8M | ||
| Q3 25 | $385.0K | $-56.5M | ||
| Q2 25 | $-786.0K | $-49.7M | ||
| Q1 25 | $-4.0M | $32.6M | ||
| Q4 24 | $3.3M | $-32.7M | ||
| Q3 24 | $-1.8M | $-40.9M | ||
| Q2 24 | $6.7M | $-46.0M | ||
| Q1 24 | $3.9M | $-56.0M |
自由现金流率FEIMRGNX
| Q4 25 | -6.6% | -174.0% | ||
| Q3 25 | 2.8% | -189.9% | ||
| Q2 25 | -3.9% | -232.8% | ||
| Q1 25 | -20.9% | 36.6% | ||
| Q4 24 | 20.8% | -154.2% | ||
| Q3 24 | -11.8% | -168.9% | ||
| Q2 24 | 42.8% | -206.2% | ||
| Q1 24 | 28.4% | -358.5% |
资本支出强度FEIMRGNX
| Q4 25 | 3.6% | 1.7% | ||
| Q3 25 | 5.6% | 1.7% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 3.3% | 5.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 5.3% | 2.1% | ||
| Q1 24 | 2.3% | 3.6% |
现金转化率FEIMRGNX
| Q4 25 | -0.29× | — | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | -0.24× | 5.53× | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | -0.60× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 32.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
